BioCentury
ARTICLE | Financial News

BMS, uniQure gene therapy deal advances

August 11, 2015 1:54 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) selected three undisclosed targets under its gene therapy collaboration with uniQure N.V. (NASDAQ:QURE), triggering a $15 million payment to uniQure. The collaboration, announced in April, grants BMS exclusive access to uniQure's gene therapy technology platform for up to 10 targets (see BioCentury Extra, April 6).

BMS also took an additional $38 million equity stake in uniQure through the purchase of 1.3 million shares at $29.67, bringing its total stake to 9.9%. The company holds two warrants to increase its stake in uniQure to 19.9% as the partnership progresses. ...